NCT02363335View on ClinicalTrials.gov

The Role of Phosphodiesterase Inhibitors in Incretin Secretion

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

February 13, 2015

Primary Completion Date

September 19, 2016

Study Completion Date

September 19, 2016

Conditions
Healthy Volunteers
Interventions
OTHER

Placebo

mixed meal

OTHER

Roflumilast/Sitagliptin

Both Roflumilast and Sitagliptin together

OTHER

Sitagliptin

This is already known to increase GLP-1 \& GIP secretion.

OTHER

Roflumilast

This is already known to increase GLP-1 \& GIP secretion

Trial Locations (1)

21224

National Institute of Aging, Clinical Research Unit, Baltimore

All Listed Sponsors
lead

National Institute on Aging (NIA)

NIH

NCT02363335 - The Role of Phosphodiesterase Inhibitors in Incretin Secretion | Biotech Hunter | Biotech Hunter